DrugPatentWatch Database Preview

Details for Patent: 6,641,834

« Back to Dashboard

Which drugs does patent 6,641,834 protect, and when does it expire?

Patent 6,641,834 protects ALPHAGAN P and is included in two NDAs.

Protection for ALPHAGAN P has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-seven patent family members in nineteen countries.

Summary for Patent: 6,641,834

Title:	Compositions containing alpha-2-adrenergic agonist components
Abstract:	Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
Inventor(s):	Olejnik; Orest (Coto de Coza, CA), Kerslake; Edward D. S. (Charlestown, MA)
Assignee:	Allergan Sales, Inc. (Irvine, CA)
Application Number:	10/236,566
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 6,641,834

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Allergan	ALPHAGAN P	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	021770-001	Aug 19, 2005		RX	Yes	Yes					Y
Allergan	ALPHAGAN P	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	021262-001	Mar 16, 2001	AT	RX	Yes	Yes					Y

Non-Orange Book US Patents Family Members for Patent 6,641,834

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,858,961	Compositions containing alpha-2-adrenergic agonist components
9,295,641	Compositions containing alpha-2-adrenergic agonist components
9,687,443	Compositions containing alpha-2-adrenergic agonist components
6,627,210	Compositions containing .alpha.-2-adrenergic agonist components

International Patents Family Members for US Patent 6,641,834

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	033539
Australia	2001273269
Australia	2005220199
Australia	2005280259